Pharmafile Logo
Pharmafocus logo
Advanced Search
code

BenevolentAI announces licensing agreement with Janssen

November 8, 2016
Research and Development Janssen, Johnson & Johnson, artificial intelligence

BenevolentAI, a British artificial intelligence company, announced a licensing agreement to develop a select number of drug candidates with Janssen, …

News
irina_antonijevic_image

Irina Antonijevic appointed as chief medical officer at vasopharm

November 8, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

vasopharma, a privately held biopharmaceutical company, announced on 8 November that it had appointed Irina Antonijevic as their chief medical …

Appointment
cvnef_xxeaeoa4i

Free Pharmacovigilance Webinar: Only one day left to register!

November 8, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmacovigilance

There is only one more day to register for our free pharmacovigilance webinar on 10 November, in association with PrimeVigilance. …

News
digital_pharma

FDA clears digital sensor for GSK inhaler

November 8, 2016
Manufacturing and Production, Sales and Marketing FDA, GSK, GlaxoSmithKline, Propeller Health, ellipta

The FDA has given 510(k) clearance to a smart inhaler sensor developed by Propeller Health for use with GlaxoSmithKline’s Ellipta …

News
abbott_humira

Coherus knocked back by AbbVie’s Humira patent protection

November 8, 2016
Manufacturing and Production, Sales and Marketing AbbVie, Coherus, Humira

Coherus Biosciences, a developer of biosimilars, has suffered a blow in their petition for Inter Partes Review (IPR) of one …

News
sicorbio

Teva antihypertensive generic duo gets FDA thumbs up

November 7, 2016
Manufacturing and Production, Sales and Marketing Azor, FDA, Teva, Tribenzor

Teva has received the approval from the US Food and Drug Administration (FDA) for its generic hypertension treatments Tribenzor (olmesartan …

News
oystein_soug

Targovax announce the appointment of CEO

November 7, 2016

Oystein Soug was announced as the new CEO of Targovax, a clinical stage immuno-oncology company dedicated to the development of …

Appointment
biogen_austria_238

Biogen and Ionis’ spinal muscular atrophy drug meets primary endpoint

November 7, 2016
Manufacturing and Production, Research and Development Biogen, Ionis, spinal muscular atrophy

Biogen and Ionis Pharmaceuticals have released news that their investigational treatment for spinal muscular atrophy (SMA), Spinraza (nusinersen), met the …

News
banner_3

Free Pharmacovigilance Webinar: Just two days left to register!

November 7, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Webinar, pharmacovigilance, primevigilance

There are only two more days to register for our free pharmacovigilance webinar on 10 November, in association with PrimeVigilance. …

News
south_korea_flag

South Korea’s workforce expands 27% in last four years

November 7, 2016
Manufacturing and Production, Sales and Marketing Employment, manufacturing, production, south korea

South Korea’s pharmaceutical workforce has expanded by 27% in the last four years. The growth in jobs is can be …

News
shutterstock_274590824

GSK launches patent infringement action against Pfizer

November 7, 2016
Sales and Marketing Bexsero, trumenba

GlaxoSmithKline has filed a patent infringement lawsuit against rival Pfizer over the alleged copying of its popular meningococcal group B …

News
amgen_hq

FDA approves first therapy for paediatric psoriasis treatment

November 7, 2016
Sales and Marketing Amgen, Enbrel, paediatric, psoriasis

Amgen’s Enbrel has been given approval by the FDA for expanded use to treat children with chronic moderate-to-severe plaque psoriasis. …

News
cmglee_cambridge_cancer_research_web

Cancer Research UK enters new oncology partnership

November 7, 2016
Sales and Marketing Cancer Research UK, TYG Oncology, oncology

Cancer Research UK (CRUK) and its commercial arm, Cancer Research Technology (CRT), haven entered into an agreement with TYG Oncology …

News
nestle_health_sciences

Nestle backs allergy biotech Aimmune to the tune of $145 million

November 7, 2016
Sales and Marketing Aimmune, allergy therapeutics, nestle

Nestle Health Science has invested $145 million in return for a 15% stake in Aimmune Therapeutics. Aimmune pursues food-allergy therapies …

News

Merck KGaA invests €250 million in production in China

November 4, 2016
Manufacturing and Production China, Merck KGaA, Nantong, manufacturing

Merck KGaA inaugurated their Nantong pharmaceutical plant on 4 November. At the same time, Merck also announced that it plans …

News
top_ten_1

Top Ten articles in the pharma industry this week

November 4, 2016
Medical Communications November, news, pharmaceutical, top 10, top ten, top ten stories

This week has seen pharmaceutical companies release their third quarter profits, good news for some whilst others have attempted to …

News
shutterstock_138095450

Sanofi, Lilly & Novo accused of pricing collusion

November 4, 2016
Manufacturing and Production, Medical Communications, Sales and Marketing

Bernie Sanders has continued his assault on pharma pricing after calling out Eli Lilly earlier this week by implicating Lilly, …

News

Lonza grows manufacturing capability by opening further site

November 4, 2016
Medical Communications Lonza, drug product services, manufacturing

Lonza, a Swiss multinational chemical and biotechnology company, has opened a new manufacturing facility in Basel, where their headquarters is …

News
astrazeneca_building_white

AstraZeneca’s post-heart attack drug gets NICE recommendation

November 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack

AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …

News

Blood cancer sufferers to receive early access to BMS’ Opdivo

November 3, 2016
Medical Communications Bristol-Myers Squibb, lyphoma, opdivo

Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …

News
The Gateway to Local Adoption Series

Latest content

Ofichem brings all brands under single trading name

April 23, 2026

Carvolix strengthens its Board of Directors, advisory board and governance structure

April 23, 2026

Under-Secretary of State for Health Innovation and Safety visits new building on University of Huddersfield’s NHIC

April 22, 2026

Incyclix Bio announces new additions to the Board

April 22, 2026

Remedy Plan Therapeutics Appoints Jotin Marango as CFO and CBO

April 21, 2026